Eusol Biotech Co.,Ltd.

As of December 31, 2025, Eusol Biotech Co.,Ltd. has 137.00M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Eusol Biotech Co.,Ltd. maintains a current ratio of 31.59, meaning it holds 31.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.41, indicating elevated leverage, while an interest coverage ratio of -359.50 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -11.11, reflecting losses generated across the asset base. Inventory turnover of 1.51 indicates how many times Eusol Biotech Co.,Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on April 9, 2026, Eusol Biotech Co.,Ltd.'s stock has declined approximately 64.62% over the past 52 weeks. The 50-day moving average sits at 5.80, while the 200-day moving average is 6.37.

Over the twelve months ended December 31, 2025, Eusol Biotech Co.,Ltd. posted a gross margin of 32.16, reflecting its pricing power and cost economics. The operating margin of -2,267.45 and net profit margin of -1,945.88 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -3.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of December 31, 2025, Eusol Biotech Co.,Ltd. has an Altman Z-Score of -5.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.